Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...
The future of cancer drug research just might be in Omaha, Nebraska, between a Panda Express and a Mattress Firm. A big draw is speed: Nordquist says he can open a trial in as little as two weeks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback